Whitehawk Therapeutics, Inc.
Clinical trials sponsored by Whitehawk Therapeutics, Inc., explained in plain language.
-
New targeted cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first human study of a new experimental cancer drug called HWK-007. Researchers are testing it in adults with advanced ovarian, endometrial, or non-small cell lung cancers that have stopped responding to standard treatments. The main goals are to find the safest dose …
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
First patients test promising new weapon against tough gynecologic cancers
Disease control Recruiting nowThis is the first-ever study in people of a new targeted cancer drug called HWK-016. It aims to find a safe and effective dose for adults with advanced ovarian or endometrial cancer that has spread or come back. The study will test the drug alone and in combination with another c…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC